Key Players
Competitive Landscape
Future Market Insights lists Berkeley Advanced Biomaterials first by estimated share, followed by CAM Bioceramics, Fluidinova, SigmaGraft Biomaterials and APS Materials. Himed, Zimmer Biomet, Medtronic and Stryker are named without share ranges. Qualification files, particle control and the ability to scale from development to production without requalification separate the specialist producers.
Between mid-2025 and mid-2026, activity centred on coatings, printed implants and dental grafts. Promimic reported a new US process plant that tripled capacity, Himed and Adva Cera announced a printed-implant route to production in May 2026, and HUDENS BIO received US clearance for BONTREE PLUS in March 2026.[4][5][8] Coating capacity and nano-grade dossiers will decide which suppliers gain qualified positions by 2036.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| May 2026: Himed and Adva Cera announced a partnership for 3D-printed calcium phosphate components.[5] | Demand for printed bioceramic implants | Material plus manufacturing bundles | Printed dental, orthopedic and spinal components |
| March 2026: FDA cleared HUDENS BIO's graft of 30% hydroxyapatite and 70% octacalcium phosphate.[8] | Dental grafting volumes | Korean graft makers entering the US | Export of qualified graft grades |
| February 2026: Promimic reported more than 2.6 million implants with HAnano Surface in clinical use.[4] | Coated implant demand | Coating service capacity expanding | Coating services for new implant designs |
| October 2025: The AJRR 2025 report covered more than 4.4 million procedures, with the count up 8.8%.[1] | Joint replacement volumes | Growing registry base | Demand for coated implants and graft blends |
| July 2025: SCCS allowed 29.5% for nano-hydroxyapatite in toothpaste and 10% in mouthwash.[2] | Higher EU limits in the SCCS opinion | Nano-hydroxyapatite in oral care products | Nano grades for toothpaste and mouthwash |
Source: Future Market Insights, Hydroxyapatite Market Report, 2026-2036.
Material producers sell qualification and consistency, coating specialists sell process capacity, and device brands set the hydroxyapatite content of each platform.
Who leads the hydroxyapatite market?
Future Market Insights places Berkeley Advanced Biomaterials first, at an estimated 18% to 22% share, followed by CAM Bioceramics at 12% to 16% and Fluidinova at 10% to 14%. SigmaGraft Biomaterials is estimated at 8% to 12% and APS Materials at 5% to 9%.
Which companies have documented product positions?
Medtronic (Mastergraft, 15% HA) and HUDENS BIO (BONTREE PLUS, 30% HA) publish composition data, Zimmer Biomet documents HA coating on the Oxford cementless knee, and Promimic reports more than 2.6 million implants with HAnano Surface.[6][8][7][4]
What should buyers evaluate before approving a supplier?
Device makers should confirm quality system certification, coating conformity to the relevant standard, lot-to-lot phase purity and crystallinity data, and the supplier's ability to support EU MDR files before the 31 December 2027 deadline.[9] Oral care buyers in the EU should check particle shape and aspect-ratio data against the SCCS criterion of at least 87% of particles at an aspect ratio of 3 or less.[2]
How is competition expected to change through 2036?
Price competition in bulk calcium phosphates will stay separate from qualified grades, and coating capacity, nano-grade dossiers and printed-implant partnerships will set the pace. Graft makers such as HUDENS BIO gaining US clearances will add competition in dental grades.[8]
Representative Company Overview
| Company | Positioning | Recent development |
|---|---|---|
| Himed | Partner of Adva Cera on 3D-printed calcium phosphate components, covering design and optimization | May 2026: partnership with Adva Cera announced.[5] |
| Promimic | Supplier of HAnano Surface for implants | February 2026: reported more than 2.6 million implants in clinical use.[4] |
| HUDENS BIO | Gwangju maker of a hydroxyapatite and octacalcium phosphate dental graft | March 2026: FDA cleared BONTREE PLUS.[8] |
| Zimmer Biomet | Oxford cementless partial knee with hydroxyapatite coating | November 2024: US supplemental PMA approval reported.[7] |
Research Methodology
The companies included in the report represent current market structure and do not indicate a market-share ranking. Company inclusion is based on the market report and on dated filings, releases and trade reports on hydroxyapatite materials, coatings and devices. Market size, segment leaders and country CAGRs come from the market report. Company, registry and regulatory facts come from company releases, regulators, registries and trade press.
